biostudies-literatureUnknown76(1)Wu LJiangsu Hengrui Pharmaceuticals Co., Ltd.Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA-mutated/homologous recombination-deficient (HRD) patients, is lacking. This study compared combined fuzuloparib (a PARPi) plus apatinib (a vascular endothelial growth factor receptor-2 inhibitor) with either fuzuloparib or placebo as first-line maintenance in patients with advanced OC. Patients who had newly diagnosed, advanced OC and responded to first-line, platinum-based chemotherapy were randomized 2:2:1 to receive combined fuzuloparib (100 mg twice daily) plus apatinib (375 mg daily), fuzuloparib (150 mg twice daily) plus placebo, or double-placCA: a cancer journal for clinicianse70042https://www.ebi.ac.uk/biostudies/studies/S-EPMC12645347biostudies-literatureFuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.PMC12645347Zhang GWu LHu YWu QGuo XWang DHao MZhang HLin ZWang JWang KWang LWen HWang QChen ZWang WXia BZhang CWu XAn RYang HLi GXie XChen MChen LLi QLi NGao QYang XLi XLi YLin AYang YYao DLou GDi WJiang KCai LYu JCheng WMeng YCheng XTang JWei SZhou HZhao HZhou QYin RZhu JHuang YZhang YHuang XPan LDuan WfalseFuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA-mutated/homologous recombination-deficient (HRD) patients, is lacking. This study compared combined fuzuloparib (a PARPi) plus apatinib (a vascular endothelial growth factor receptor-2 inhibitor) with either fuzuloparib or placebo as first-line maintenance in patients with advanced OC. Patients who had newly diagnosed, advanced OC and responded to first-line, platinum-based chemotherapy were randomized 2:2:1 to receive combined fuzuloparib (100 mg twice daily) plus apatinib (375 mg daily), fuzuloparib (150 mg twice daily) plus placebo, or double-plac2026-01-01T00:00:00Z2026 Jan-Feb2026-06-06T01:13:18.718Z2026-05-24T03:12:16.688ZS-EPMC126453474128796910.3322/caac.70042